David Rubin, MD, FACG

University of Chicago Medicine, Inflammatory Bowel Disease Center

Poster(s):

• P0726 - Cumulative Response to Guselkumab Through Week 24 of Induction in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0727 - Efficacy and Safety of Filgotinib as Induction and Maintenance Therapy for Crohn’s Disease: Results From the Phase 3 Randomized, Double-Blind, Placebo-Controlled DIVERSITY1 Study
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0728 - Impact of Etrasimod on Blood Pressure and Hypertension: Data From the Etrasimod Ulcerative Colitis Clinical Program
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0729 - Efficacy and Durability of Ozanimod by Baseline Endoscopic Disease Activity in Advanced Therapy–Naive Ulcerative Colitis Patients Suboptimally Controlled on Conventional Therapies
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0730 - Guselkumab Improves Abdominal Pain and Bowel Urgency Symptoms in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0731 - PRA023 Improved Health-Related Quality of Life as Measured by IBDQ-32 in a Phase 2 Trial in Patients with Moderately to Severely Active Ulcerative Colitis
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0732 - Efficacy of Upadacitinib in Patients With Crohn’s Disease Activity Index-Based Eligibility Criteria: Post Hoc Analysis of U-EXCEL, U-EXCEED, and U-ENDURE Phase 3 Trials
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0733 - Mirikizumab Sustains Improvement on Health-Related Quality of Life in Patients With Crohn’s Disease at Week 104: A Phase 2 Study Analysis Using the SF-36
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0734 - Long-Term Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0735 - The Effect of Patients’ Current Ulcerative Colitis Disease Severity Perception on Prevalence and Experiences of Bowel Urgency: Results from the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0736 - The Addition of Bowel Urgency Improvement to the Achievement of Clinical Response and Remission Was Associated with Better Quality of Life in Patients with Ulcerative Colitis from Mirikizumab Phase 3 Trials
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0737 - Safety of Filgotinib in Crohn’s Disease Compared with Ulcerative Colitis: Data from the Phase 3 DIVERSITY1 and Phase 2b/3 SELECTION Studies
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0738 - The Addition of Bowel Urgency Improvement to the Achievement of Clinical Response or Remission Was Associated with Better Work Productivity in Patients with Ulcerative Colitis from Mirikizumab Phase 3 Trials
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0739 - Health-Related Quality of Life From the Inflammatory Bowel Disease Questionnaire in Patients with Ulcerative Colitis Stratified by Prior & Concomitant Therapies: Results From the Etrasimod ELEVATE UC Clinical Program
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT